Ivabradine Improves Quality of Life in Subjects with Chronic Heart Failure Compared to Treatment with β-Blockers: Results of a Multicentric Observational APULIA Study

Pharmacology

Volumn 92, Issue 5-6, 2014, Pages 276-280

  Riccioni, G ^a,g   Masciocco, L ^b   Benvenuto, A ^b   Saracino, P ^b   De Viti, D ^d   Massari, F ^c   Meliota, G ^e   Buta, F ^e   Speziale, G ^f  

^a Cardiology Unit   (Italy)

^b Lastaria Hospital   (Italy)

^c Division of Neurotraumatology   (Italy)

^d Santa Maria Hospital   (Italy)

^e Ambulatory Cardiology   (Italy)

^f ANTHEA HOSPITAL   (Italy)

^g NONE   (Italy)

Author keywords

Blockers; Bisoprolol; Carvedilol; Chronic stable angina; Health related quality of life; Heart failure; Ivabradine; SF 36 questionnaire

Indexed keywords

BISOPROLOL; CARVEDILOL; IVABRADINE;

ADULT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART RATE; HEART REPOLARIZATION; HEMODYNAMICS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SINUS RHYTHM; SMOKING; SYSTOLIC BLOOD PRESSURE; WELLBEING; EMOTION; INTERVIEW; OBSERVATIONAL STUDY;

ADRENERGIC BETA-ANTAGONISTS; AGED; BENZAZEPINES; BISOPROLOL; BLOOD PRESSURE; CARBAZOLES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84893025145     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000355169     Document Type: Article

References (19)

1. Fonseca C: Diagnosis of heart failure in primary care. Heart Failure Rev 2006; 11: 95-107.
2. Borlaug BA, Paulus WJ: Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670-679.
3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Mc- Donagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2013; 15: 361-362.
4. Mosterd A, Hoes AW: Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146.
5. Bonnemeier H, Richardt G, Potratz J, Wiegand UK, Brandes A, Kluge N, Katus HA: Circadian profile of cardiac autonomic nervous modulation in healthy subjects: Differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol 2003; 14: 791-799.
6. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators: Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): A randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.
7. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators: Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376: 875-885.
8. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW: Meta-analysis: Betablocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784 -794.
9. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The task force for the Diagnosis and Treatment of Acute and chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
10. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L: Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992; 305: 160-164.
11. Diaz A, Bourassa MG, Guertin MC, Tardif JC: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974.
12. Kolloch R, Legler UF, Champion A, Cooper- Dehoff RM, Handberg E, Zhou Q, Pepine CJ: Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: Findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29: 1327-1334.
13. Antoni ML, Boden H, Delgado V, Boersma E, Fox K, Schalij MJ, Bax JJ: Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2012; 33: 96-102.
14. Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JG: Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: A systematic review. Eur Heart J 2005; 26: 778-793.
15. Jorde UP, Vittorio TJ, Kasper ME, Arezzi E, Colombo PC, Goldsmith RL, Ahuja K, Tseng CH, Haas F, Hirsh DS: Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: Time to pace Eur J Heart Fail 2008; 10: 96- 101.
16. Riccioni G: Ivabradine: An intelligent drug for the treatment of ischemic heart disease. Molecules 2012; 17: 13592-13604.
17. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K: Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study. Eur Heart J 2011; 32: 2395-2404.
18. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN: Prognostic value of changes in N-terminal probrain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008; 52: 997-1003.
19. Riccioni G, Prencipe G, Benvenuto A, Masciocco L, Ventra S, Rizzo U, Russi C, Speziale G: Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers. Pharmacology 2013; 91: 35-38.